stockportfolio.pro
Stocks / DSGN vs RLMD
DSGN vs RLMD
Design Therapeutics, Inc. and Relmada Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Design Therapeutics, Inc. (DSGN) | Relmada Therapeutics, Inc. (RLMD) | |
|---|---|---|
| Market cap | $0.6B | $0.7B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-69.79M | $-57.39M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -32.8% | -66.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DSGN — free Open RLMD — freeFrequently asked questions
Which is bigger, DSGN or RLMD?
Relmada Therapeutics, Inc. is larger by market capitalization — $0.7B versus $0.6B.
Which grows faster, DSGN or RLMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.